Recent Advances in Antibody-Drug Conjugates for Breast Cancer Treatment

Author(s): Shanshan Deng, Zongtao Lin, Wei Li*

Journal Name: Current Medicinal Chemistry

Volume 24 , Issue 23 , 2017

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer
Call for Editor


Breast cancer is the most common cancer in women, with roughly half a million deaths per year worldwide. Among various approaches for breast cancer treatment, chemotherapy is predominantly used for patients at stages II-IV, and monoclonal antibody (mAb) therapy is used for patients with human epidermal growth factor receptor 2 (HER2) overexpression. Integrating the tumor specificity provided by unique mAbs and cytotoxicity of small molecule drugs, antibody-drug conjugates (ADCs) are a series of smart chemotherapeutics that have recently shown great promise in treating a number of cancer types. ADCs are designed to selectively attack and kill cancer cells with minimal toxicity to normal tissues. Ado-Trastuzumab emtansine (T-DM1) was the first and only ADC approved by the US Food and Drug Administration for HER2-positive breast cancer. Following the success of T-DM1, many novel ADCs have been developed, and their anticancer efficacies are currently undergoing preclinical or clinical investigation. The development of ADCs is a rapidly progressing field, and this review aims to summarize the most recent advances in ADCs targeting breast cancer over the past five years (2011-2016). The review highlights compositions and mechanisms of action of these newly developed ADCs and discusses current challenges and future directions of developing new ADCs for improved treatment of breast cancer.

Keywords: Antibody-drug conjugates, breast cancer, drug-antibody ratios, monoclonal antibody, targeted therapy, antigen.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2017
Page: [2505 - 2527]
Pages: 23
DOI: 10.2174/0929867324666170530092350
Price: $65

Article Metrics

PDF: 98
HTML: 21